VIVS

VivoSim Labs Inc

0.1428

Nov 09 • 8:36 AM ET +0.0012 (0.85%)

Healthcare Biotechnology USA Nano NASD

Peers: CSBR ABSI CRL LTRN CERT ISPC HBIO MEDP LAB QTRX

Index	-
Market Cap	2.37M
Enterprise Value	1.02M
Income	-12.34M
Sales	0.11M
Book/sh	-0.73
Cash/sh	0.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	15
IPO	Feb 14, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	21.54
P/B	-
P/C	1.42
P/FCF	-
EV/EBITDA	-
EV/Sales	9.27
Quick Ratio	1.70
Current Ratio	1.70
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-4.47
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	39.18% 28.81%
Sales past 3/5Y	-29.26% -
EPS Y/Y TTM	-194.95%
Sales Y/Y TTM	-21.13%
EPS Q/Q	77.51%
Sales Q/Q	-51.35%
Earnings	-
EPS/Sales Surpr.	46.15% -26.83%

Insider Own	16.62%
Insider Trans	0.36%
Inst Own	11.12%
Inst Trans	0.46%
ROA	-155.93%
ROE	-343.10%
ROIC	-
Gross Margin	-73.21%
Oper. Margin	-10116.96%
Profit Margin	-11016.07%
SMA20	-8.23%
SMA50	-30.63%
SMA200	-85.97%
Trades

Shs Outstand	16.59M
Shs Float	13.83M
Short Float	4.33%
Short Ratio	0.23
Short Interest	0.60M
52W High	3.40 -95.80%
52W Low	0.14 5.23%
Volatility	8.28% 10.26%
ATR (14)	0.02
RSI (14)	35.06
Beta	1.55
Rel Volume	0.14
Avg Volume	2.57M
Volume	17,636

Perf Week	-6.85%
Perf Month	-20.71%
Perf Quarter	-59.50%
Perf Half Y	-89.65%
Perf YTD	-92.11%
Perf Year	-93.45%
Perf 3Y	-99.18%
Perf 5Y	-99.81%
Perf 10Y	-99.98%
Recom	3.00
Target Price	64.80
Prev Close	0.14
Price	0.14
Change %	0.85%

Consensus

Hold

Avg. Price Target

$64.80

Implied Upside

+45,278.2%

Analysts5incl. previous ratings

Rating Distribution3 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Dec 13, 2018	Initiated	HH.C. Wainwright	Buy	$2.50	+1,650.7%
Nov 10, 2017	Downgrade	RRaymond James	Outperform → Mkt Perform
Jan 25, 2017	Initiated	RRaymond James	Outperform
Aug 11, 2015	Downgrade	CCantor Fitzgerald	Buy → Hold
Jun 29, 2015	Initiated	PPiper Jaffray	Overweight	$5	+3,401.4%
Jun 29, 2015	Initiated	JJefferies	Buy	$5	+3,401.4%

Nov-03-26 08:05AM	VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test (GlobeNewswire) -6.33%
Oct-21-26 08:05AM	VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling (GlobeNewswire)
Oct-07-26 08:05AM	VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods (GlobeNewswire) -5.15%
Sep-16-26 08:05AM	VivoSim Labs Unveils New NAMkind Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs (GlobeNewswire)
Sep-01-26 08:05AM	VivoSim Labs to Add Rat Liver Model to NAMkind Platform (GlobeNewswire)
05:52PM	Loading…
Aug-12-26 05:52PM	VivoSim: Fiscal Q1 Earnings Snapshot (Associated Press) -5.81%
Aug-06-26 08:05AM	VivoSim Provides Financial and Listing Compliance Update (GlobeNewswire) -9.24%
Jul-21-26 10:28AM	VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS) (InvestorsHub) -10.87%
08:05AM	VivoSim Enters China with First Commercial Sales of NAMkind Toxicology Screening and Efficacy Testing Services (GlobeNewswire)
Jul-16-26 08:30AM	VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor (GlobeNewswire) -28.06%
Jul-15-26 10:46AM	VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth (InvestorsHub)
08:05AM	VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 (GlobeNewswire)
Jul-14-26 05:12PM	VivoSim: Fiscal Q4 Earnings Snapshot (Associated Press)
Jun-29-26 08:05AM	VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting (GlobeNewswire)
Apr-28-26 08:05AM	VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results - Without Animal Testing (GlobeNewswire)
08:05AM	Loading…
Apr-01-26 08:05AM	VivoSim Announces Pricing of up to a $4 Million Public Offering (GlobeNewswire) +13.29%
Mar-24-26 08:05AM	VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs (GlobeNewswire)
Mar-03-26 08:05AM	VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales (GlobeNewswire) -12.73%
Feb-11-26 08:05AM	VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego (GlobeNewswire)
Feb-02-26 06:59AM	NIO January Deliveries Nearly Double Year On Year (GuruFocus.com) -16.78%
Jan-29-26 04:05PM	VivoSim Expands Asia-Pacific Access to NAMKind Human-Based Toxicology Services Through New Distributor Agreement in Korea and China (GlobeNewswire) +71.76%
Jan-06-26 08:05AM	VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer (GlobeNewswire)
Jan-02-26 07:03AM	NIO Posts Record December and Q4 Deliveries as 2025 Volumes Surge (GuruFocus.com)
Dec-01-25 10:52AM	Nio Stock Slumps After Surprise November Delivery Drop (GuruFocus.com)
06:25AM	NIO Just Posted a 76% Delivery Surge--Here's What Investors Might Be Missing (GuruFocus.com)
Nov-04-25 07:51AM	NIO Stock Pops as EV Maker Smashes Delivery Record With 92% Surge (GuruFocus.com) -6.78%
Oct-01-25 05:45AM	NIO Stock Soars Past 52-Week High After Record Deliveries (Benzinga) +9.93%
Sep-02-25 05:40AM	NIO, XPeng, Li Auto Log Strong August Deliveries Highlighting China's EV Momentum (Benzinga)
Aug-14-25 08:05AM	VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer (GlobeNewswire)
Aug-12-25 04:44PM	VivoSim: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +6.05%
08:05AM	Loading…
May-13-25 08:05AM	VivoSim's NAMKind Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference (GlobeNewswire)
May-07-25 08:05AM	VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference (GlobeNewswire)
Apr-24-25 08:05AM	VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market (GlobeNewswire) -8.33%
Apr-23-25 08:05AM	VivoSim to Carry Forward Organovo 3D Bioprinting (GlobeNewswire)
Apr-02-25 08:05AM	Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements (GlobeNewswire)
Mar-27-25 08:05AM	Organovo Provides Business Update (GlobeNewswire) -13.50%
Mar-25-25 11:25AM	Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company (GlobeNewswire) -5.02%
Mar-19-25 08:05AM	Organovo Announces Reverse Stock Split (GlobeNewswire) -32.61%
Mar-11-25 07:00AM	Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-06-25 08:05AM	Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises (GlobeNewswire)
Feb-25-25 08:05AM	Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company (GlobeNewswire) +244.17%
Feb-19-25 09:17AM	Organovo: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Jan-06-25 08:05AM	Organovo Announces Appointment of Norman Staskey as Chief Financial Officer (GlobeNewswire) +7.15%
Nov-20-24 08:05AM	Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting (GlobeNewswire)
Nov-13-24 08:06AM	Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases (GlobeNewswire)
Nov-08-24 04:15PM	Organovo: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -6.60%
Jul-16-24 08:05AM	Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis (GlobeNewswire) -8.55%
Jun-03-24 11:52AM	ONVO Stock Earnings: Organovo Holdings Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace) +5.78%
May-21-24 08:05AM	Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease (GlobeNewswire)
May-14-24 11:00AM	Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) (GlobeNewswire)
May-09-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-08-24 08:00PM	Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering (GlobeNewswire) +5.49%
Apr-15-24 08:13AM	Organovo's fatty liver disease drug meets main goal in mid-stage study (Reuters) +33.65%
08:05AM	Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo (GlobeNewswire)
Mar-28-24 08:32PM	Top 15 3D Printing Companies in the US (Insider Monkey)
Feb-08-24 05:52PM	Organovo: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -10.00%
Jan-25-24 08:05AM	Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress (GlobeNewswire)
Jan-09-24 08:05AM	Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress (GlobeNewswire)
Dec-06-23 08:05AM	Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results (GlobeNewswire) -6.04%
Nov-13-23 08:05AM	CORRECTION Organovo Highlights FXR314 Combination Therapy Potential and Plan (GlobeNewswire) +5.93%
Nov-10-23 05:08AM	Organovo: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -7.53%
Nov-08-23 08:05AM	Organovo Highlights FXR314 Combination Therapy Potential and Plan (GlobeNewswire) -5.18%
Oct-10-23 07:18AM	ONVO: A Company With Great Technology to Impact Health Care (Zacks)
Sep-08-23 12:46PM	Organovo to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-25-23 07:36PM	Is Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com) -13.16%
Aug-23-23 08:05AM	Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data (GlobeNewswire) +5.43%
Jul-12-23 03:01AM	Net Asset Value(s) (Business Wire)
May-25-23 10:49AM	Cathie Wood is Selling These 12 Stocks in 2023 (Insider Monkey)
Mar-21-23 08:05AM	Organovo Announces FXR Program (GlobeNewswire)
Feb-10-23 05:12AM	Will Organovo Holdings (NASDAQ:ONVO) Spend Its Cash Wisely? (Simply Wall St.) -17.86%
Nov-15-22 08:05AM	Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohns Disease Drug Candidates (GlobeNewswire)
Sep-06-22 08:20AM	Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +13.42%
08:05AM	Organovo Announces Postponement of Annual Meeting of Stockholders (GlobeNewswire)
Jul-08-22 08:05AM	We're Not Very Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Rate (Simply Wall St.) +29.17%
May-17-22 08:05AM	Organovo Achieves 3D Tissue Model for Crohns Disease (GlobeNewswire) +5.86%
Mar-03-22 10:13PM	Why Organovo Holdings, Inc. Stock Soared 49.7% This Week (Motley Fool) -11.34%
Mar-01-22 08:05AM	UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents (GlobeNewswire) +5.90%
Feb-23-22 08:05AM	Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents (GlobeNewswire) +5.47%
Feb-18-22 04:00PM	Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:00PM	Organovo Welcomes New Sr. Vice President of Strategy and Business Development (GlobeNewswire)
Feb-12-22 02:09PM	10 3D Printing Companies to Watch in 2022 (Insider Monkey)
Feb-04-22 10:11AM	Cathie Wood Targets Illiquid Assets and Limits Exits in New Fund (Bloomberg)
Feb-02-22 12:00PM	Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents (GlobeNewswire)
Jan-21-22 11:37AM	15 Worst Stock Picks of Cathie Wood (Insider Monkey)
Jan-10-22 12:00PM	Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk (GlobeNewswire)
Dec-30-21 09:24AM	Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation (Simply Wall St.)
Nov-30-21 08:05AM	Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022 (GlobeNewswire)
Sep-17-21 04:10PM	Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum (GlobeNewswire) -7.57%
Jun-22-21 10:17AM	/C O R R E C T I O N from Source -- RBC Global Asset Management Inc./ (PR Newswire) +5.02%
Jun-15-21 11:38AM	Is Organovo Holdings Inc (ONVO) A Good Stock To Buy? (Insider Monkey)
Mar-02-21 08:05AM	Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE) (GlobeNewswire)
Feb-07-21 09:19AM	15 Biggest 3D Companies in the World (Insider Monkey)
Sep-03-20 04:05PM	Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -5.75% -11.54%
Aug-17-20 08:05AM	Organovo Announces One-for-Twenty Reverse Stock Split (GlobeNewswire) -13.52%
Jun-10-20 03:43PM	Hedge Fund Sentiment Is Stagnant On Organovo Holdings Inc (ONVO) (Insider Monkey) -7.54%
Apr-08-20 10:32AM	Edited Transcript of ONVO earnings conference call or presentation 9-Nov-17 10:00pm GMT (Thomson Reuters StreetEvents) +13.63%
07:53AM	The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO (Benzinga)
Apr-07-20 04:12PM	Organovo Announces Termination of Merger Agreement with Tarveda Therapeutics (Business Wire)
Apr-02-20 08:00AM	Organovo Holdings Founder Calls on Board of Directors to Accept Stockholders Opposition to the Illogical Merger With Tarveda Therapeutics (GlobeNewswire) -13.19%
Mar-31-20 06:30PM	Organovo Holdings, Inc. Reminds Stockholders About Adjourned Special Meeting of Stockholders (Business Wire) +43.36% -28.07%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lialin Tony Serge	Chief Commercial Officer	Aug 31 '26	Buy	0.28	10,000	2,804	10,000	Sep 01 04:01 PM

VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.

Executive Chairman & Corporate SecretaryMr. Keith E. Murphy

PresidentMr. Norman Staskey

Ph.D.Dr. Amar A. Sethi M.D.

Chief Commercial OfficerMr. Tony Lialin

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VIVS

VivoSim Labs Inc

Upgrade your Finviz experience